Joseph E. Gilliam Sells 59,801 Shares of Glaukos Co. (NYSE:GKOS) Stock

Glaukos Co. (NYSE:GKOS) COO Joseph E. Gilliam sold 59,801 shares of the stock in a transaction on Monday, April 8th. The shares were sold at an average price of $100.47, for a total transaction of $6,008,206.47. Following the transaction, the chief operating officer now directly owns 101,845 shares in the company, valued at $10,232,367.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Glaukos Price Performance

Shares of GKOS stock opened at $99.26 on Friday. The company has a debt-to-equity ratio of 0.77, a current ratio of 5.34 and a quick ratio of 4.78. The firm’s 50-day moving average is $91.53 and its two-hundred day moving average is $79.84. Glaukos Co. has a 12 month low of $45.38 and a 12 month high of $102.33. The company has a market capitalization of $4.91 billion, a PE ratio of -35.71 and a beta of 1.08.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.07). Glaukos had a negative return on equity of 22.67% and a negative net margin of 42.79%. The firm had revenue of $82.40 million for the quarter, compared to analysts’ expectations of $81.00 million. During the same period last year, the firm earned ($0.53) earnings per share. Glaukos’s revenue for the quarter was up 15.7% on a year-over-year basis. Analysts predict that Glaukos Co. will post -2.18 earnings per share for the current year.

Hedge Funds Weigh In On Glaukos

A number of institutional investors have recently bought and sold shares of GKOS. National Bank of Canada FI acquired a new stake in shares of Glaukos during the fourth quarter valued at about $46,000. GAMMA Investing LLC acquired a new stake in shares of Glaukos during the fourth quarter valued at about $55,000. Quadrant Capital Group LLC increased its position in shares of Glaukos by 54.8% during the fourth quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier’s stock valued at $74,000 after acquiring an additional 329 shares during the last quarter. Silverarc Capital Management LLC acquired a new stake in shares of Glaukos during the second quarter valued at about $71,000. Finally, Tower Research Capital LLC TRC increased its position in shares of Glaukos by 257.8% during the first quarter. Tower Research Capital LLC TRC now owns 1,238 shares of the medical instruments supplier’s stock valued at $62,000 after acquiring an additional 892 shares during the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

GKOS has been the topic of several research reports. Wells Fargo & Company raised their price target on shares of Glaukos from $83.00 to $103.00 and gave the stock an “overweight” rating in a research note on Thursday, February 22nd. Needham & Company LLC raised their price target on shares of Glaukos from $105.00 to $108.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. Mizuho raised their price target on shares of Glaukos from $85.00 to $100.00 and gave the stock a “neutral” rating in a research note on Thursday. Truist Financial reissued a “buy” rating and issued a $110.00 price target on shares of Glaukos in a research note on Monday. Finally, JPMorgan Chase & Co. raised shares of Glaukos from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $66.00 to $91.00 in a research note on Thursday, December 21st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Glaukos has an average rating of “Moderate Buy” and a consensus price target of $99.80.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.